CN107614501A - 羟基嘌呤类化合物及其应用 - Google Patents

羟基嘌呤类化合物及其应用 Download PDF

Info

Publication number
CN107614501A
CN107614501A CN201680029214.9A CN201680029214A CN107614501A CN 107614501 A CN107614501 A CN 107614501A CN 201680029214 A CN201680029214 A CN 201680029214A CN 107614501 A CN107614501 A CN 107614501A
Authority
CN
China
Prior art keywords
methyl
base
diketone
reaction solution
pyrimidine
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201680029214.9A
Other languages
English (en)
Other versions
CN107614501B (zh
Inventor
吴凌云
张鹏
张丽
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.
Original Assignee
Medshine Discovery Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medshine Discovery Inc filed Critical Medshine Discovery Inc
Publication of CN107614501A publication Critical patent/CN107614501A/zh
Application granted granted Critical
Publication of CN107614501B publication Critical patent/CN107614501B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C07D473/10—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3 with methyl radicals in positions 3 and 7, e.g. theobromine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
    • C07D473/04—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms
    • C07D473/06—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two oxygen atoms with radicals containing only hydrogen and carbon atoms, attached in position 1 or 3
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pain & Pain Management (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

本发明公开了一系列羟基嘌呤类化合物及其作为PDE2或TNFα抑制剂的应用，具体公开了式(I)所示化合物、其互变异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (11)

  1. PCT国内申请，权利要求书已公开。
CN201680029214.9A 2015-05-20 2016-05-05 羟基嘌呤类化合物及其应用 Active CN107614501B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201510260884 2015-05-20
CN2015102608849 2015-05-20
PCT/CN2016/081103 WO2016184313A1 (zh) 2015-05-20 2016-05-05 羟基嘌呤类化合物及其应用

Publications (2)

Publication Number Publication Date
CN107614501A true CN107614501A (zh) 2018-01-19
CN107614501B CN107614501B (zh) 2020-01-14

Family

ID=57319487

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680029214.9A Active CN107614501B (zh) 2015-05-20 2016-05-05 羟基嘌呤类化合物及其应用

Country Status (3)

Country Link
US (1) US10618898B2 (zh)
CN (1) CN107614501B (zh)
WO (1) WO2016184313A1 (zh)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113461643A (zh) * 2021-07-20 2021-10-01 韶远科技（上海)有限公司 一种4-甲基苯磺酸[(3-氟氧杂环丁烷-3-基)甲基]酯的合成方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
CN104428302A (zh) * 2012-07-31 2015-03-18 勃林格殷格翰国际有限公司 4-甲基-2,3,5,9,9b-五氮杂-环戊二烯并[a]萘
WO2016054971A1 (zh) * 2014-10-09 2016-04-14 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
PA8539301A1 (es) 2001-02-14 2002-09-30 Warner Lambert Co Inhibidores de la metaloproteinasa de la matriz
EP1953162B9 (de) 2001-02-24 2012-10-31 Boehringer Ingelheim Pharma GmbH & Co. KG Xanthinderivate, deren Herstellung und deren Verwendung als Arzneimittel
BR0312736A (pt) 2002-07-17 2005-04-26 Warner Lambert Co Associação de um inibidor carboxìlico alostérico da metaloproteinase-13 de matriz com celecoxib ou valdecoxib
DE10235225B3 (de) 2002-08-01 2004-01-22 Albert-Ludwigs-Universität Freiburg Verfahren zur Durchführung chemischer Reaktionen unter Beteiligung von an fluorierten Trägermaterialien über Fluor-Fluor-Wechselwirkungen adsorbierten Verbindungen, fluoriertes Trägermaterial sowie die Verwendung des Trägermaterials
US8207175B2 (en) 2005-06-21 2012-06-26 University Court Of The University Of Dundee Inhibitor compounds
TW201623257A (zh) 2014-05-09 2016-07-01 奧利安公司 藥理活性之喹唑啉二酮衍生物
PL3193880T3 (pl) 2014-09-19 2020-09-07 Eli Lilly And Company Hamowanie kanału jonowego receptora przejściowego potencjału A1
CN105566324B (zh) * 2014-10-09 2020-04-03 广东众生睿创生物科技有限公司 羟基嘌呤类化合物及其应用
JP6511692B2 (ja) * 2015-05-20 2019-05-15 グアンドン レイノベント バイオテック カンパニー リミテッド ヒドロキシプリン類化合物及びその応用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1994024133A1 (en) * 1993-04-09 1994-10-27 Cell Therapeutics, Inc. Ring-substituted cell signaling inhibitors
CN104428302A (zh) * 2012-07-31 2015-03-18 勃林格殷格翰国际有限公司 4-甲基-2,3,5,9,9b-五氮杂-环戊二烯并[a]萘
WO2016054971A1 (zh) * 2014-10-09 2016-04-14 南京明德新药研发股份有限公司 羟基嘌呤类化合物及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
AARON T. LARSEN ET AL: "Predictable Stereoselective and Chemoselective Hydroxylations and Epoxidations with P450 3A4", 《J. AM. CHEM. SOC.》 *

Also Published As

Publication number Publication date
WO2016184313A1 (zh) 2016-11-24
CN107614501B (zh) 2020-01-14
US20180148451A1 (en) 2018-05-31
US10618898B2 (en) 2020-04-14

Similar Documents

Publication Publication Date Title
EP3652168B1 (en) 5-membered and bicyclic heterocyclic amides as inhibitors of rock
CN107635989B (zh) 作为溴结构域抑制剂的苯并咪唑衍生物
JP6600365B2 (ja) Ｊａｋ阻害剤
CN109923116B (zh) 作为pde2抑制剂的[1,2,4]三唑并[1,5-a]嘧啶衍生物
CA2933480A1 (en) Inhibitors of lysine specific demethylase-1
WO2021043322A1 (zh) 氮杂环庚烷并嘧啶类衍生物及其医药用途
TWI583684B (zh) Sulfonamide derivatives and their pharmaceutical applications
CN105228997A (zh) Carm1抑制剂及其用途
CN107001371B (zh) 羟基嘌呤类化合物及其应用
CN116888108B (zh) 新型egfr降解剂
CN110267959B (zh) 作为PI3Kδ抑制剂的咪唑并[1,5-A]吡嗪衍生物
WO2017082759A1 (ru) {3-[(7н-пирролo[2,3-d]пиримидин-4-ил)-азолил]азетидин-3-ил}-ацетонитрилы в качестве ингибиторов янус киназ
JP6511692B2 (ja) ヒドロキシプリン類化合物及びその応用
CN111655689B (zh) 吡唑并吡啶酮化合物
CN111655690B (zh) 吡唑并吡啶酮化合物
CN109661391A (zh) S1p1激动剂及其应用
CN109641909A (zh) 雷帕霉素信号通路抑制剂的机理靶标及其治疗应用
CN118176195A (zh) 吡唑[3,4-d]嘧啶-3-酮类化合物及其医药用途
CN118139864A (zh) 新化合物
CN107614501A (zh) 羟基嘌呤类化合物及其应用
TW202334167A (zh) 作為ｅｒｂｂ２抑制劑之稠合四環喹唑啉衍生物
JP2019518052A (ja) Ａｋｔ阻害剤としてのジヒドロピラゾロアゼピン系化合物
TW202214634A (zh) 雜環化合物及其衍生物
TWI690529B (zh) 羥基嘌呤類化合物及其應用
JP2022515622A (ja) チエノピリジノン化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
TA01 Transfer of patent application right

Effective date of registration: 20181219

Address after: Room 1701-1705, Main Building, Rongyi Building, No. 5 Information Road, Songshan Lake Hi-tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant after: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

Address before: 523325 Information Industry Park, Shilong Industrial Zone, Shilong Town, Dongguan, Guangdong, West Lake

Applicant before: Zhongsheng Pharmaceutical Co., Ltd., Guangdong

TA01 Transfer of patent application right
CB02 Change of applicant information

Address after: 3406a, jinzhonghuan international business building, 3037 Jintian Road, Fu'an community, Futian street, Futian District, Shenzhen City, Guangdong Province

Applicant after: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

Address before: Room 1701-1705, Main Building, Rongyi Building, No. 5 Information Road, Songshan Lake Hi-tech Industrial Development Zone, Dongguan City, Guangdong Province

Applicant before: Guangdong Zhongsheng Ruichuang Biotechnology Co., Ltd.

CB02 Change of applicant information
GR01 Patent grant
GR01 Patent grant